合并肾功能不全的多发性骨髓瘤治疗进展
摘要
多发性骨髓瘤(multiplemyeloma,MM)患者约20%~40%在疾病发展的某个阶段合并肾功能不全,这些伴有肾功能不全患者对传统化疗反应差,早期病死率高,生存时间明显低于不伴肾功能不全的患者。本文对此类患者的治疗进展作一综述。
出处
《临床肾脏病杂志》
2013年第5期199-201,共3页
Journal Of Clinical Nephrology
参考文献18
-
1Hutchison CA, batuman V, brehrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol,2011,8:43-51.
-
2陈楠.多发性骨髓瘤肾脏损害诊断和治疗[J].内科理论与实践,2007,2(6):373-375. 被引量:8
-
3Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma. Clin Exp Med, 2007,7 : 83-97.
-
4Stringer S, Basnayake K, Hutchison C, et al. Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney). Bone Marrow Res. Volume 2011: Article ID 493697,9 pages, doi : 10. 1155/2011/493697.
-
5王丽娟(综述),宋强(审校).复发性与难治性多发性骨髓瘤的治疗进展[J].国际输血及血液学杂志,2011,34(6):517-522. 被引量:3
-
6Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in com- bination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haema- tol,2004,73:98-103.
-
7王小山(综述),陈钰(审校).多发性骨髓瘤治疗进展[J].国际输血及血液学杂志,2011,34(5):349-352. 被引量:4
-
8Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or re- fractory multiple myeloma patients with impaired renal function. Cancer, 2010,116:3807-3814.
-
9Klein U, Neben K, Hielscher T, et al. Lenalidomide in combina- tion with dexamethasone: Effective regimen in patients with re- lapsed or refractory multiple myeloma complicated by renal im- pairment. Ann Hematol, 2011,90 : 429-439.
-
10DAmato R J, Loughnan MS, Flynn E, et al. Thalidomide is an in- hibitor of angiogenesis. Proc Natl Acad Sci USA. 1994,91:4082- 4O85.
二级参考文献77
-
1Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma, 2007,48(2) :337-341.
-
2Chanan-KhanAA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure:a multicenter retrospective study. Blood,2007, 109 (6):2604-2606.
-
3Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone- containing regimes and the impact of novel agents. Haematologica, 2007, 92(4):546-549.
-
4Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention with new insights from in vitro and in vivo models of renal injury. Am J Nephrol,2009, 22(1) :17-28.
-
5Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol,2010, 84(3) :223-228.
-
6Dimopoulos MA, Roussou M, Gavriatopoulou M, et aI. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive faetors. Clin Lymphoma Myeloma, 2009, 9 (4) : 302- 306.
-
7Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can he reversed by bortezomib-doxorubicin- dexamethasone in multiple myeloma:results of a phase Ⅱ study. J Clin Oncol,2010, 28(30) :4635-4641.
-
8Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res, 2010, 34(10):1395- 1397.
-
9Li J, Zhou DB, Jiao L, et al. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma, 2009,9 (5) : 394-398.
-
10Qayum A, Aleem A, AI Diab AR, et al. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Saudi J Kidney Dis Transpl, 2010, 21 (1) : 63-68.
共引文献22
-
1杨成,兰天飙,江亚芳.以肾脏损害为首发症状的多发性骨髓瘤临床分析[J].中华临床医师杂志(电子版),2011,5(14):4231-4234. 被引量:2
-
2杨倩,刘章锁,肖静.以急性肾衰竭为首发表现的多发性骨髓瘤1例报告并文献复习[J].中国误诊学杂志,2009,9(22):5525-5526.
-
3吕亚莉.血沉在多发性骨髓瘤肾病诊断中的价值[J].现代实用医学,2010,22(3):324-325. 被引量:4
-
4宋晓晨,周芳.硼替佐米联合左旋苯丙氨酸氮芥预处理自体干细胞移植治疗多发性骨髓瘤三例[J].白血病.淋巴瘤,2012,21(4):239-240. 被引量:1
-
5张萌,刘丽萍,郭友逢,李智,莫穗林.汉黄芩素对多发性骨髓瘤细胞周期及P-Wee1和P-Akt蛋白表达的影响[J].热带医学杂志,2012,12(11):1301-1303. 被引量:3
-
6汪娟,傅琤琤,吴德沛,孙爱宁,薛胜利,辛雪,胡晓慧,王荧,仇惠英,金正明,苗瞄,唐晓文,韩悦,马骁,何广胜,常伟荣,陈苏宁.自体造血干细胞移植治疗多发性骨髓瘤的回顾性疗效分析[J].中华医学杂志,2013,93(2):114-118. 被引量:13
-
7王岩,黄仲夏,李寒.转化生长因子β在轻链致骨髓瘤肾病上皮间质转化过程中的作用[J].国际移植与血液净化杂志,2013,11(2):19-21.
-
8黄仲夏.多发性骨髓瘤的诊治进展[J].临床药物治疗杂志,2013,11(5):4-7. 被引量:4
-
9刘佳慧,邱录贵,安刚.肿瘤相关髓系细胞在多发性骨髓瘤免疫微环境形成中的作用[J].白血病.淋巴瘤,2018,27(11):690-693. 被引量:6
-
10蒋端凤,贺艳娟,李林,林文远,董敏.全反式维甲酸联合粒细胞集落刺激因子对骨髓瘤细胞生长、分化及RARα2表达的影响[J].浙江大学学报(医学版),2014,43(3):305-312. 被引量:1
-
1杜建新.脑出血外科手术治疗的进展[J].中国脑血管病杂志,2006,3(4):183-186. 被引量:22
-
2冯书梅,马玲波,张林.瓣膜置换并冠状动脉旁路移植术后病人的监护[J].护理研究(中旬版),2006,20(3):703-704. 被引量:3
-
3张妍.高龄股骨转子间骨折患者常见并发症原因及预防对策[J].江苏医药,2007,33(11):1184-1184. 被引量:3
-
4石学银,马丽,徐海涛,何星颖,邹最,袁红斌,傅宏,傅志仁.肝移植术后早期死亡的危险因素分析[J].第二军医大学学报,2008,29(12):1421-1425. 被引量:4
-
5史洪涛,申东彦,邢桃红,尚东.急性门静脉血栓形成15例诊治体会[J].郑州大学学报(医学版),2008,43(3):629-630. 被引量:1
-
6章岳峰,赵琦峰,胡超.老年心脏瓣膜置换术患者的临床分析[J].中华老年医学杂志,2013,32(1):22-24. 被引量:11
-
7常保国,安雪军,蔚晋斌.完全性颈脊髓损伤早期死亡的危险因素分析[J].中国药物与临床,2017,17(1):119-120. 被引量:4
-
8李天亮,刘宽荣.中西医结合治疗化疗反应的临床疗效观察[J].光明中医,2016,31(9):1303-1305. 被引量:1
-
9王红禄,孙家邦,陈宏.暴发性胰腺炎死亡原因分析[J].首都医科大学学报,2005,26(2):200-202. 被引量:2
-
10王有贵.2145例胸部创伤的诊治体会[J].安徽卫生职业技术学院学报,2011,10(1):22-23.